If so, I need your opinion. We conduct many Phase I studies for phramaceutical and biotech companies. Many protocols clearly indicate that the blind will be broken for the purpose of the analytical laboratory and only subjects on active drug will be analyzed.
Placebo controlled study designs are important for the purpose of safety, efficacy.
If a protocol is measuring some pharmacodynamic parameter or surrogate end point then one will collect the information on Placebo subjects. We are currently involved in a protocol which requires platelet aggregation studies with ADP, TRAP and Arachidonic Acid and the lab is measuring the platelet aggregation on all subjects. However the analytical lab will measure drug concentrations on only the subjects who received active drug. I have not seen too many Open Label studies with Placebo control as suggested by Parsad in his E-mail. I donot know the significance of placebo in an open label study.